PharmaWatch: NeoTX & AstraZeneca (MedImmune) Enter into Immuno-Oncology Clinical Trial Collaboration

Feb 13, 2019 | Immunotherapy, Immunotherapy for Cancer, Leading Pharma, Oncology

Immuno-oncology

NeoTX Therapeutics has entered into a clinical collaboration with MedImmune (AstraZeneca’s biologics research and development arm) for phase Ib/II studies investigating NeoTX’s naptumomab estafenatox in combination with IMNINZI (durvalumab).  Expected to start in 2019, naptumomab is a leading drug in NeoTX’s novel selective T cell Redirection (STR) platform.

0 Comments

Pin It on Pinterest